849106-01-0 Usage
Type
Chemical compound
Usage
Organic synthesis and drug development
Structure
Methyl ester derivative of BOC-protected piperidine carboxylic acid with a 4-chlorophenyl group attached to the piperidine ring
Potential Applications
a. Pharmaceutical industry as a building block for the synthesis of various bioactive molecules
b. Precursor for the preparation of drug candidates
c. Controlled release and targeted delivery of active ingredients in drug formulations due to BOC protecting group
d. Development of new materials
e. Research tool in biochemistry and medicinal chemistry
Functional Groups
a. BOC protecting group
b. Methyl ester
c. 4-chlorophenyl group
d. Piperidine ring
e. Carboxylic acid
Properties
a. Stability due to BOC protecting group
b. Reactivity with various reagents for further functionalization
c. Solubility in organic solvents
d. Potential bioactivity due to the presence of the piperidine ring and 4-chlorophenyl group
Synthesis
Likely involves the reaction of a BOC-protected piperidine carboxylic acid with a 4-chlorophenyl group-containing compound, followed by methyl esterification
Purification
May require techniques such as column chromatography or recrystallization to obtain the desired purity
Safety
As with any chemical compound, proper handling, storage, and disposal protocols should be followed to minimize risks to human health and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 849106-01-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,9,1,0 and 6 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 849106-01:
(8*8)+(7*4)+(6*9)+(5*1)+(4*0)+(3*6)+(2*0)+(1*1)=170
170 % 10 = 0
So 849106-01-0 is a valid CAS Registry Number.
849106-01-0Relevant articles and documents
ACYL SULFONAMIDE NAV1.7 INHIBITORS
-
Page/Page column 56, (2018/05/24)
The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (I)
Piperidine derivatives and methods of use
-
Page/Page column 16-17, (2008/06/13)
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment